normocalcemic patients with cancer who had been successfully treated for an episode of hypercalcemia were enrolled in a randomized , multisite , double-blind , placebo-controlled trial designed to determine the efficacy of maintenance oral etidronate in preventing the recurrence of moderate to severe hypercalcemia ( serum calcium level , greater than 11.5 mg/dl [ greater than 2.87 mmol/l ] ) .
C0086268
etidronate
C0020437
hypercalcemia